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Dementia with Lewy Bodies (DLB) is a common neurodegenerative disorder with poor prognosis and 
mainly unknown pathophysiology. Heritability estimates exceed 30% but few genetic risk variants have 
been identified. Here we investigated common genetic variants associated with DLB in a large European 
multisite sample. We performed a genome wide association study in Norwegian and European cohorts 
of 720 DLB cases and 6490 controls and included 19 top-associated single-nucleotide polymorphisms 
in an additional cohort of 108 DLB cases and 75545 controls from Iceland. Overall the study included 
828 DLB cases and 82035 controls. Variants in the ASH1L/GBA (Chr1q22) and APOE ε4 (Chr19) loci 
were associated with DLB surpassing the genome-wide significance threshold (p < 5 × 10−8). One 
additional genetic locus previously linked to psychosis in Alzheimer’s disease, ZFPM1 (Chr16q24.2), 
showed suggestive association with DLB at p-value < 1 × 10−6. We report two susceptibility loci for 
DLB at genome-wide significance, providing insight into etiological factors. These findings highlight the 
complex relationship between the genetic architecture of DLB and other neurodegenerative disorders.
Dementia with Lewy Bodies (DLB) is the second most common type of neurodegenerative dementia, accounting 
for 15% of dementia patients. DLB overlaps clinically, pathologically and genetically with Alzheimer’s disease 
(AD) and Parkinson’s disease (PD). Clinically, DLB is characterized by cognitive impairment, parkinsonism, 
psychotic symptoms like visual hallucinations, fluctuating cognition with pronounced variations in attention and 
alertness and REM sleep behaviour disorder. Reduced uptake on CIT-SPECT or myocardial scintigraphy and 
polysomnography with confirmation of REM sleep without atonia have been included as indicative biomarkers 
in the diagnostic criteria1. We have previously shown the clinical diagnostic criteria for probable DLB to be both 
sensitive (77%) and highly specific (94%) as compared to a pathological DLB diagnosis. Furthermore, we have 
found DLB to have higher costs, more neuropsychiatric symptoms, a more rapid cognitive decline, shorter time 
until nursing home admission, shorter survival and higher caregiver distress as compared to AD2–8.
In some families, DLB occurs with autosomal dominant heritance at an age of onset <65 years. In these fami-
lies, alpha-synuclein (SNCA) multiplications or point mutations have been described9,10. DLB is however typically 
late onset (i.e. onset after 65 years of age) and sporadic, and the proportion of phenotypic variance that can be 
explained by >250,000 SNPs on the NeuroX array has been estimated to 31% with substantial genetic overlap 
with both AD and PD11. Indeed, previous genetic studies have suggested associations of APOE, GBA, SNCA and 
SCARB2 with DLB in both neuropathologically and clinically diagnosed cases12. Data from another GWAS of 
DLB were recently presented and confirmed APOE e4, SNCA and GBA, and in addition suggested CNTN1 to 
be associated with DLB13. Regarding APOE, the strongest genetic risk factor for AD, we showed that the APOE 
ε4 allele increases and the APOE ε2 allele decreases the risk of developing DLB14. GBA, the gene encoding the 
lysosomal enzyme glucocerebrosidase, is associated with PD risk and cognitive decline in PD15,16. In DLB, GBA 
mutations have been reported in 7.8% of cases (odds ratio (OR) ~8), even up to 31% in Ashkenazi Jews, suggest-
ing that GBA is a stronger risk factor for DLB than for PD17. Moreover, whole exome sequencing studies have 
identified rare and pathogenic variants in GBA, PSEN1 or APP in 4.4–25% of patients with pathologically or clin-
ically diagnosed DLB18,19. However, none of the AD associated common variants identified in large genome-wide 
association studies (GWAS) have been associated to DLB besides APOE.
Notwithstanding these interesting results from early genetic studies, the individual genetic risk factors that 
specifically contribute to the common and sporadic late onset form of DLB have remained relatively unexplored 
compared to PD and AD, largely due to the lack of large sample series providing adequate statistical power for 
GWAS. In the current study, we collected DNA and genotyped samples from the Norwegian DemGene consor-
tium and the European DLB consortium (E-DLB), and performed a GWAS applying a two-stage meta-analysis 
approach and follow-up in an independent cohort. We investigated whether common genetic variants are associ-
ated with DLB, aiming to elucidate the molecular mechanisms underlying the disease.
Methods
Participants. Three discovery cohorts were included in the study (Cohorts 1, 2 and 3). We collected samples 
from the Norwegian Dementia Genetics Network (DemGene) and from the European DLB consortium (E-DLB). 
Cohort 1 included DemGene and three European centres (Strasbourg, Amsterdam and Lund), and consisted of 
478 cases and 1322 controls. An additional Norwegian population cohort of 4875 controls was added. Cohort 2 
included two European centres both from Barcelona and consisted of 242 cases and 293 controls. Cohort 3 sam-
ples were collected in Iceland and consisted of 108 cases and 75545 controls. Altogether 828 DLB cases and 82110 
controls were included in this study, see Supplementary material and Supplemental (S.) Table 1 for details. All 
research was performed in accordance with relevant guidelines/regulations, and informed consent was obtained 
from all participants and/or their legal guardians.
Genotyping. DNA was extracted from whole blood. We genotyped Cohort 1 on the Illumina Infinium 
Omni Express-24 v1.1 platform (Illumina Inc., San Diego, CA, USA) at deCODE Genetics (Reykjavik, Iceland) 
in concordance with the standard Illumina protocol. We genotyped Cohort 2 samples with the Illumina 
Infinium Omni Express Exome-8v1.3 chip. Cohort 3 samples were genotyped on Illumina’s HumanHAP300, 
HumanHAP300-Duo and HumanCNV370 bead arrays. We conducted assignment of genotypes according to 
the standard Illumina protocol in GenomeStudio software V2011.1 version 1.9.4. We tested for plate effects and 
other batch effects by a number of association tests described in detail under supplementary methods. Markers 
exhibiting high rates of genotyping missingness (above 5%), minor allele frequency (MAF) below 1% or show-
ing departure from Hardy Weinberg equilibrium (p < 1 × 10−4 calculated for controls) were excluded from the 
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analyses. Individuals showing high rates of genotyping missingness (above 5%), cryptic relatedness (pairwise 
Identity-By-Descent PI_HAT above 20%) or genome-wide heterozygosity (outside mean ± 5 SD of the sample) 
were removed from the analyses. Further, sex-check was performed based on the homozygosity estimate of X 
chromosome markers implemented in PLINK.
Association analysis. We performed association analysis in two stages. Due to data regulations and ethical 
approvals regarding data sharing, we performed genome-wide association analyses on Cohorts 1 and 2 inde-
pendently and combined the results through meta-analysis to obtain Stage 1 results. HRC imputation was not 
accessible for cohort 1 due to national regulations in Norway. To reduce possible genomic inflation or overcor-
rection, the results from the Stage 1 meta-analysis were corrected for genomic inflation before we performed 
meta-analysis with Cohort 3 to obtain Stage 2 results.
Genotypes from Cohort 1 samples were imputed onto the European reference haplotypes from the 1000 
Genomes Project (GRCh37/hg19 assembly) Phase 3 using MACH (http://www.sph.umich.edu/csg/abecasis/
MACH). We excluded variants with MAF lower than 0.01 or R-squared quality metric (INFO) > 0.5. We per-
formed principal component analysis (PCA) on Cohort 1 pre-imputation data using PLINK 1.9 (https://www.
cog-genomics.org/plink2) to account for population stratification. The association analysis by logistic regres-
sion on dosage data using PLINK 1.9 included gender, age and the two first principal components as covariates. 
Genomic inflation factors were calculated as the ratio of the median of the empirically observed distribution of 
the association chi-square statistic to the expected median20.
Genotypes from Cohort 2 samples were imputed onto the GRCh37/hg19 assembly with ShapeIT & Minimac3 
using the haplotype reference consortium HRC version r1.1 reference data at the imputation server of the 
University of Michigan. PCA was done independently for Cohort 2 because there was no relatedness to samples 
from Cohort 1. Logistic regression was performed using PLINK 1.9 using gender, age and the top two genetic 
principal components as covariates. The genomic inflation factor was calculated as previously described.
To obtain Stage 1 results, variants from Cohort 1 and Cohort 2 were mapped to each other using GRCh37/
hg19 assembly. All variants with allele discrepancies across cohorts were discarded. We performed meta-analysis 
of Cohort 1 and Cohort 2 using PLINK 1.9 with fixed effects inverse-variance weighted effect sizes. Biases from 
different cohorts due to genotype array and imputation procedures are mitigated through correction on the 
inflation factor. The results were verified using METAL meta-analysis tool (http://csg.sph.umich.edu/abecasis/
Metal). To identify independently associated loci, we used FUMA’s SNP2GENE function to define lead SNPs 
and genomic risk loci21. Graphical representations including quantile-quantile plots and Manhattan plots were 
performed in R using the qqman package (http://cran.r-project.org/web/packages/qqman).
We selected variants with Stage 1 meta-analysis p-value < 1 × 10−6 for follow up in Cohort 3 (Iceland) and 
used the same approach described above to meta-analyse the results in Stage 222.
Functional mapping and annotation (FUMA) of GWAS. We utilized FUMA to functionally anno-
tate our Stage 1 results21. FUMA incorporates 18 biological data repositories such as the Genotype-Tissue 
Expression (GTEx), the Encyclopedia of DNA Elements (ENCODE), the Roadmap Epigenomics Project and 
chromatin interaction information. FUMA requires GWAS summary statistics and its outputs include multiple 
tables and figures containing extensive information on, e.g., functionality of SNPs in genomic risk loci, including 
protein-altering consequences, gene-expression influences, open-chromatin states as well as three-dimensional 
(3D) chromatin interactions. Functionally annotated variants are subsequently mapped to prioritized genes based 
on (i) physical position mapping on the genome, (ii) expression quantitative trait loci (eQTL) mapping and (iii) 
3D chromatin interactions (chromatin interaction mapping). Biological information for each prioritized gene is 
provided to gain insight into previously associated diseases. On top of the single gene level analyses, FUMA also 
provides information on association overrepresentation in sets of differentially expressed genes (DEG) to identify 
tissue specificity of prioritized genes. We refer to the details of methods and repositories of FUMA in21.
Ethics committee approval. All cohorts and sites providing samples for this study have local ethics 
approval for DNA collection and data sharing, and the names of local ethics committees are provided in the in 
the supplemental materials. In Norway the joint study was approved by the Regional Committees for Medical and 
Health Research Ethics in Mid Norway.
Results
From Cohort 1, we obtained genotypes for 719,755 SNPs and performed imputation to obtain 7,769,477 
high-quality variants. We performed association using 478 DLB cases and 1322 controls, see S. Table 1. After 
controlling for population stratification using PCA (S. Fig. 1A), the genomic inflation factor Lambda was 1.005 
(S. Fig. 2A). We found genome-wide significance on rs2230288 (closest gene GBA, p = 3.77 × 10−8) and rs429358 
(closest gene APOE, p = 3.21 × 10−9). The regional association plots for this locus is visualized in S. Fig. 3.
To increase the power of our study, we included additional Norwegian population controls in the study, see 
S. Table 1. Using two principal components (S. Fig. 1B), the addition of population controls increased inflation 
to a Lambda of 1.244, possibly due to inflation from the additional controls. We verified the inflation using LD 
Score Regression and found the intercept at 1.2094, consistent with Lambda. Quantile-quantile plots for Cohort 
1 before and after genomic correction are given in S. Fig. 2. After correction, the strongest associations in Cohort 
1 remain with rs2230288 (p = 1.77 × 10−10) and rs429358 (p = 4.13 × 10−9).
We found 45 SNPs associated to DLB at p < 5 × 10−6 with strong associations in Chromosomes 1 and 19; a 
summary of our findings from Cohort 1 is given in S. Table 2A.
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From Cohort 2, we analysed 7,570,659 successfully imputed variants. The genomic inflation factor Lambda 
was 1.031. Quantile-quantile plots for Cohort 2 are given in S. Fig. 2. The Cohort 2 study revealed 9 SNPs asso-
ciated to DLB at p < 5 × 10−6; also with strong associations in Chromosome 19, see S. Table 2B. After individual 
analyses of discovery Cohorts 1 and 2, we performed a Stage 1 meta-analysis of 6,963,063 variants (898 were dis-
carded due to allele mismatches). The meta-analysis genomic inflation factor Lambda was 0.865, possibly due to 
overcorrection for the genomic inflation in Cohort 1. We corrected the chi-square statistics of the meta-analysis at 
fixed ORs, see the quantile-quantile plots in S. Fig. 2. Genome-wide Stage 1 results are visualized as a Manhattan 
plot in Fig. 1.
After correction, Stage 1 analysis revealed 108 SNPs associated with DLB at p < 5 × 10−6 (S. Table 2C). The 
statistical power of our study is estimated to be 0.085 (MAF = 0.05) to 0.395 (MAF = 0.1) to 0.823 (MAF = 0.2) 
for SNPs with genomic risk ratio GRR = 1.5 and GRR = 1.2, shown in S. Fig. 4. GRR values were chosen based 
on ORs of discoveries of earlier DLB studies13. We followed up on 18 of these SNPs, which were successfully ana-
lysed in an independent sample from Iceland (Cohort 3) and performed a Stage 2 meta-analysis. Because stage 
2 meta-analysis included only 18 selected SNPs instead of a genome-wide analysis, this result was not corrected 
for genomic inflation.
From the Stage 2 meta-analysis, we found two susceptibility regions associated with DLB surpassing 
genome-wide significance, p < 5 × 10−8. We found APOE ε4 related SNPs at genome-wide significance, repre-
sented by rs429358 (OR = 2.28, p = 6.15 × 10−17, see Table 1 for details). A regional association plot of the APOE 
locus from Stage 1 meta-analysis is presented in S. Fig. 5A. From a recent large study, we found that this SNP is 
identical to the reported top hit (OR = 2.40, p = 1.05 × 10−48) in Guerreiro et al.13.
We also discovered a DLB-associated locus on Chromosome 1, represented by rs12734374 (closest gene: 
ASH1L, OR = 4.31, p = 1.33 × 10−9, see Table 1 and regional association plots in S. Fig. 5B). This SNP is located 
in the same genomic region of rs2230288, the strongest hit in Cohort 1 which was not successfully imputed 
in Cohort 2, but had implicated GBA. Furthermore, in another study, we found that rs12734374 is in high LD 
(R2 = 0.79) with a GBA hit, rs35749011 (OR = 2.27, p = 6.57 × 10−10 in)13. Both our APOE and ASH1L/GBA hits 
provide genome-wide significant confirmations of the findings from Guerreiro et al.13.
Furthermore, we investigated SNPs with a suggestive association to DLB. From the Stage 1 meta-analysis, we 
noted 9 SNPs at p < 1 × 10−6 in chromosome 16, represented by rs12926163 (closest gene ZFPM1, OR = 1.68, 
p = 1.45 × 10−7). These SNPs were not successfully analysed in the Icelandic cohort, and therefore we present only 
the Stage 1 result of this locus in Table 1 and S. Fig. 5C.
Next, we analysed specific gene signals reported previously in DLB for their significance under locus-wide 
Bonferroni correction for each gene. Due to the small SNP coverage in the Stage 2 analysis, we used results 
from Stage 1. We extracted variant information for SNCA (GRCh37hg19 chr4: 90,645,250-90,759,466), SCARB2 
(chr4:77,079,886-77,155,689), MAPT (chr17:43,971,748-44,105,700) and CNTN1 (chr12:41,086,244-41,466,220) 
with upstream and downstream flanking of 200kB. Regional plots of these candidate genes are shown in S. 
Fig. 5D–G.
Among the 1509 successfully imputed SNPs in the SNCA locus, the strongest association was with rs2301135 
(chr4:90,758,389, p = 5.68 × 10−5, OR = 1.40, minor allele C) and remained nearly significant after correction 
(threshold p < 3.3 × 10−5) using conservative multiple test assumptions of independent SNPs. In the SCARB2 
locus, the strongest association among the 1600 SNPs was with rs34216031 (chr4:76,971,832, OR = 1.63, 
p = 1.37 × 10−2), but its significance did not survive correction (threshold p < 3.1 × 10−5). In the MAPT locus, 
694 SNPs passed quality checks. Among these, the strongest association was with rs11652003 (chr17:44,132,659, 
OR = 0.75, p = 1.89 × 10−2) but did not withstand correction (threshold p < 7.2 × 10−5). Of note, coverage of 
MAPT is relatively poor in our genotyping and imputation procedure, see S. Fig. 5F. In the CNTN1 locus, the 
strongest association was with rs56260639 (chr12:41122583, OR = 0.50, p = 1.17 × 10−2). Despite the strong OR, 
this association did not remain significant after correction (threshold p < 2.1 × 10−5).
Finally, we investigated the potential biological roles of the resulting list of genes in brain disorders. For this, 
we performed functional analysis with FUMA GWAS21. We summarized the independent genomic risk loci from 
Figure 1. Manhattan plot of Stage 1 meta-analysis. Manhattan plot of meta-analysis of Cohorts 1 and 2 for 
genome-wide association with Dementia with Lewy Body (DLB). Genome-wide significant associations to 
DLB (threshold P < 5 × 10−8) are found in chromosomes 1 (ASH1L/GBA) and 19 (APOE), and a suggestive 
association to DLB at P < 1 × 10−6 is identified at chromosome 16 (ZFPM1). A comprehensive result of Stage 1 
is presented in Supplementary Table 2.
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Stage 1 with suggestive association p < 1 × 10−6 in S. Fig. 6. The strongest associations were close to APOE in 
Chromosome 19 and distributed in a relatively small region spanning only 41kB and 4 genes. The significant asso-
ciations in Chromosome 1, within the large haploblock containing GBA, spanned 1.2MB and up to 64 genes (see 
S. Fig. 6). We computed gene-based P-value test for protein-coding genes by mapping SNPs to genes if SNPs were 
located within the genes. The chromosome 1 genes (GBA) did not surpass the significance threshold (S. Fig. 7), 
but the chromosome 19 genes (APOE, APOC1, TOMM40) remained significant. We also found significant results 
applying the gene-based test to the gene on chromosome 16 (ZPFM1), which was suggestive at the single variant 
level. Using MAGMA tissue expression analysis, we found the strongest expression in whole blood, substantia 
nigra and spinal cord cervical level c-1. (S. Fig. 8).
FUMA prioritized 65 genes (S. Table 3, S. Fig. 9) for further functional analyses; see Methods on how genes are 
prioritized. Of note, in Chromosome 1, GBA was prioritized based on eQTL analysis (S. Fig. 9), further strength-
ening the case that our top hit implicated not only ASH1L but also GBA. From the set of 65 genes, we looked 
up tissue specific expression patterns based on GTEx v6 RNA-seq data. These are visualized as a heatmap in S. 
Fig. 10 21. Relative to other genes, we found APOE highly expressed in all tissues (S. Fig. 10A). ASH1L and GBA 
are moderately expressed and ZFPM1 has a lower gene expression relative to other genes in all tissues. Next, we 
looked at the tissue specificity for each gene. We found APOE with moderately higher expression in brain tissue 
(S. Fig. 10B), while ASH1L, GBA and ZFPM1 are not specific to brain tissues. Notably, we found higher expression 
in brain tissues for PAQR6, CHRNB2, SYT11 and APOC1 and conversely we found lower expression for PVRL2, 
LMNA and SHC1 (S. Fig. 10B).
Besides the single gene level analyses, we also identified tissue specificity of prioritized genes by looking at 
overrepresentation in sets of differentially expressed genes (DEG), see S. Fig. 11. DEG for each tissue was calcu-
lated in FUMA. We found the spinal cord cervical level c-1 and amygdala being two of the top five tissues with the 
most DEG, however, none passed Bonferroni corrected significance. The finding of the spinal cord cervical level 
c-1 is consistent with the MAGMA analysis.
Discussion
We performed a genome-wide association study based on 828 clinically diagnosed DLB cases and a large sam-
ple of 82035 controls. We confirmed the APOE ε4 allele and a locus close to ASH1L and GBA (Chr1q22) as 
significantly associated with DLB. Furthermore, we nominate a novel genetic locus near ZFPM1 as suggestively 
associated with DLB. Taken together with recent findings from another DLB GWAS13, the current results firmly 
establish APOE e4, SNCA and GBA as robust risk loci for DLB, which implicate novel disease mechanisms to be 
followed up in experimental studies.
The top-hit SNP at the 1q22 locus is located within the large haploblock containing the GBA (glucocerebrosi-
dase gene), also recently identified by Guerreiro et al.13. We note that the strongest association was in SNPs with 
relatively high LD (D′ 0.66) with rs2230288, referred to in the literature as the GBA E326K or 365 K polymor-
phism. E326K is a low frequency coding variant, which unlike the “neuropathic” GBA mutations does not cause 
Gaucher’s disease in the homozygous state. We recently demonstrated that this variant accounts for the GBA 
top-hit from a PD meta-GWAS23. E326K has also been associated with worse cognitive outcomes in PD15,16. We 
inspected the association results further and found that E326K showed the strongest of all associations at this 
locus in Cohort 1, yet was not successfully imputed in Cohort 2. We thus consider it likely that E326K is the func-
tional variant underlying this signal. With an allele frequency of >2% in the population and a strong effect on sus-
ceptibility to both PD and DLB, this variant emerges as a major risk factor for the Lewy body disorders combined. 
From a functional perspective, the GBA association highlights the importance of lysosomal pathways in DLB 
pathogenesis. GBA was recently confirmed in the largest GWAS in DLB to date (1743 DLB patients included) as 
the third most strongly associated risk gene13. SCARB2 (scavenger receptor class B member 2), encoding another 
lysosomal enzyme, has previously been associated with DLB12. While GBA is probably the most plausible causa-
tive gene in the 1q22 locus, we cannot rule out other candidate gene such as ASH1L (Absent, Small or Homeotic 
discs 1-Like). The gene encodes a histone-lysine N-methyltransferase, a member of the trithorax transcriptional 
regulators which are essential for development, organ function and fertility.
We and others have previously reported APOE (Apolipoprotein E) ε4 (Chr19q13.32) as an important genetic 
risk factor for DLB. Guerreiro et al. found the locus highly significant13, and we reported an OR for carriers of 
one copy of the APOE ε4 allele to be 2.9 for developing DLB and 4.2 for developing AD. For carriers of two cop-
ies of the APOE ε4 alleles the OR for developing DLB increased to 5.9 while the OR for developing AD was as 
high as 15.214. Bras and colleagues have reported APOE as the strongest associated risk gene in both clinically 
SNP CHR:BP
Allele 
(min/maj)
MAF 
(1KG)
MAF 
Cohort 1
MAF 
Cohort 2 Gene
Meta Stage 1 Meta Stage 2
OR P OR P
rs429358 19:45411941 C/T 0.155 0.143 0.153 APOE e4 2.79 2.00e-14 2.28 6.15e-17
rs12734374 1:155388851 T/A 0.023 0.022 0.012 ASH1L/GBA 4.29 4.29e-09 4.31 1.33e-09
rs12926163 16:88572056 C/T 0.311 0.252 0.323 ZFPM1 1.68 1.45e-07 — —
Table 1. Genetic loci with significant and suggestive associations with DLB at meta-analysis Stage 1 and Stage 
2. CHR:BP: Chromosome and Base pair location based on Build 37, Assembly Hg19. Allele (min/maj): Minor 
and major alleles; MAF: Minor Allele Frequency (on European 1000 G), Cohort 1 and Cohort 2. Gene: Nearest 
gene within 500 kB; OR, P: case-control odds-ratio and association P-values from Stage 1 combining Cohorts 1 
and 2, and Stage 2 Meta-analysis combining Cohorts 1, 2 and 3.
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and neuropathologically diagnosed DLB cases12, and this was confirmed in an expanded cohort from the same 
group recently13. Guerreiro et al. estimated the DLB SNP-heritability based on the Illumina Neuro-X content to 
be 31%, with APOE accounting for about 9%11. APOE ε4 has also been found to increase the risk of dementia 
in pure alpha-synucleinopathies in a study where its frequency was 38% in pathologically diagnosed pure AD, 
40.6% in the mixed AD and DLB group, 31.9% in pure DLB, 19.1% in Parkinson’s Disease Dementia (PDD) and 
7.2% among healthy controls24. In another AD GWAS, Lewy body pathology in the brain was associated with 
APOE variants25. Most cases with clinically diagnosed DLB will contain both Lewy bodies and AD pathology in 
the brain7.
SNCA (synuclein alpha) is the strongest associated risk gene in PD and encodes α-synuclein, which is a major 
constituent of Lewy bodies, pathological hallmark for both DLB and PD/PDD. Accumulation of α-synuclein 
aggregates have been found to create synaptic dysfunction in DLB26. The top associated variant in our data 
(rs2301135) is in LD with the SNCA signal reported as significant in the previous study by Bras et al. (r-squared 
0.98 and D′ 1.0 with rs894280 in 1000 genomes European population)12 and the secondary signal from a large 
meta-analysis of PD GWAS (r-squared 0.98 and D′ 1.0 with rs7681154)27. Both p-value and effect size of the 
SNCA association observed here are equivalent to those found in the similarly sized DLB study by Bras et al.12, 
and despite falling short of genome wide significance, we interpret this result as supportive for an SNCA associ-
ation in DLB. Deviations from other studies with respect to the strongest SNP at the locus could well arise if key 
SNPs are not well imputed across all cohorts.
Together, the identified genetic loci could be involved in a common neurobiological disease pathway in DLB. 
The normal degradation of α-synuclein is highly dependent on lysosomal function and glucocerebrosidase is 
an important enzyme in this degradation. Impaired function of glucocerebrosidase due to coding variants like 
E326K will slow down the degradation of α-synuclein thus increasing the concentration of toxic oligomers and 
thereby driving the pathological process in DLB. Inhibition of lysosomal enzymes also results in Aβ accumulation 
and aggregation. The apolipoproteins accelerate neuronal Aβ uptake, lysosomal trafficking and degradation in an 
isoform-dependent manner with apolipoprotein E3 more efficiently facilitating Aβ trafficking and degradation 
than apolipoprotein E4, a risk factor for AD and DLB28, thus linking both GBA, APOE and SNCA.
The present findings of genetic loci suggestively associated with DLB indicate interesting pathological mecha-
nisms. The chromosome 16 locus associated with DLB at p = 1.45 × 10−7 implicates ZFPM1 (Zinc finger protein, 
FOG family member 1), which is expressed in human hematopoietic tissues and in the cerebellum and is involved 
in erythroid differentiation. In one study of AD and psychosis, duplications in this gene were associated with 
psychosis in AD, a symptom highly relevant in DLB, were visual hallucinations and related delusions are core 
symptoms of the disease29. Our findings suggest other putative molecular mechanisms in DLB.
CNTN1 (contactin 1) is a glycosylphosphatidylinositol anchored neuronal membrane protein that functions 
as a cell-adhesion molecule with important roles in axonal function. It is located near the LRKK2 locus and was 
associated to PD and reported as a suggestive hit in the largest GWAS of DLB to date13. We found no signifi-
cant hits under correction in our study. Further, we found no genome-wide significant associations with MAPT 
(microtubule associated protein tau), the gene encoding tau, in our study. However, this gene was poorly covered 
in our genotyping and imputation procedure. MAPT is the second strongest associated risk gene in PD and 
is associated also with AD30. It exists on two different haplotypes, H1 and H2. H1P has been associated with 
Parkinson’s disease with dementia, whereas H1C has been associated with Alzheimer’s disease. Thus, MAPT 
would be a plausible candidate gene also for DLB due to clinical and likely genetic overlap with AD and PD 
beyond APOE31,32. The negative finding suggests that the role of MAPT variability might represent a genetic 
difference between DLB and PD, but this hypothesis needs to be further tested in larger cohorts, preferentially 
including both DLB and PD samples.
All cases included in our study were clinically diagnosed with common sporadic and late onset type of DLB. 
Cases solely diagnosed based on pathology might not always fulfil clinical diagnostic criteria during life, and 
therefore might include cases of PD and even early onset PD developing dementia in late stages. The clinically 
diagnosed DLB cases included in our study might therefore have a purer, less PD-like genetic profile than studies 
based on brain bank cases, a possible explanation for why we do not find the previously PD-associated risk loci 
like MAPT in our analysis. Diagnosing DLB clinically is challenging both because of the clinical heterogeneity 
and the overlapping AD pathology masking typical DLB core symptoms in many cases. Although diagnostic pro-
cedures differed among centres, nearly all centres are academic dementia research centres with high-level clinical 
expertise on DLB and used standardized and established procedures, including, in a subset of patients, biomark-
ers. Thus, we believe diagnoses were as accurate as can be achieved in a clinical setting, although pathological 
confirmation was available only in a subset. The clinical diagnostic criteria for probable DLB have been found to 
have high specificity and this was confirmed in a pathological study in one of the samples included in this study7. 
We therefore argue that only few cases with other diagnoses like AD can have been erroneously included in this 
sample. Adding biomarkers like (123)-FP-CIT-SPECT to the diagnostic procedure could increase diagnostic pre-
cision in DLB. AD-pathology could be detected by PET or CSF-biomarkers of amyloid and tau deposition33. The 
recently published revised diagnostic criteria for DLB are slightly different from the previous1. Whether this will 
impact on the genetic architecture of DLB cohorts is not known, however.
There are few other large cohorts diagnosed with DLB with well characterized patients, and although this 
is one of the largest studies in DLB to date – sample size is still small for a hypothesis-free GWAS approach. 
Consequently, we only had statistical power to detect signals with large effect sizes, such as APOE and GBA. We 
anticipate that GWAS with larger samples will detect more common genetic risk loci associated with DLB with 
effect sizes comparable to the vast majority of AD and PD GWAS loci. Current evidence further indicates that 
rare variants contribute significantly to the disorder, suggesting next generation sequencing approaches will also 
be important to further characterize the genetic architecture of DLB.
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DLB is increasingly recognized as a specific clinical diagnosis distinct from AD and PD both clinically and 
genetically, and has a poor prognosis with no approved treatment. To detect more of the genetic risk loci contrib-
uting to DLB pathogenesis new methods like Bayesian statistics may prove useful. This notwithstanding, larger 
samples obtainable through international collaboration are needed in a future GWAS of DLB. We therefore plan 
to collaborate to increase sample size in a next step to increase the power to detect more common genetic variants 
with small effects associated with the risk of development of DLB.
Data Availability
Genotype datasets from the Norwegian DemGene network generated and analysed during the current study 
are not publicly available due to compliance to privacy. Summary statistics are available from the corresponding 
author on reasonable request.
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